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Abstract
Introduction: Neuromedin U (NMU) is a neuropeptide with pro-inflammatory activity. The primary goal of this
study was to determine if NMU promotes autoantibody-induced arthritis. Additional studies addressed the cellular
source of NMU and sought to define the NMU receptor responsible for its pro-inflammatory effects.
Methods: Serum containing arthritogenic autoantibodies from K/BxN mice was used to induce arthritis in mice
genetically lacking NMU. Parallel experiments examined whether NMU deficiency impacted the early mast-cell-
dependent vascular leak response induced by these autoantibodies. Bone-marrow chimeric mice were generated
to determine whether pro-inflammatory NMU is derived from hematopoietic cells or stromal cells. Mice lacking the
known NMU receptors singly and in combination were used to determine susceptibility to serum-transferred
arthritis and in vitro cellular responses to NMU.
Results: NMU-deficient mice developed less severe arthritis than control mice. Vascular leak was not affected by
NMU deficiency. NMU expression by bone-marrow-derived cells mediated the pro-arthritogenic effect. Deficiency of
all of the known NMU receptors, however, had no impact on arthritis severity and did not affect the ability of NMU
to stimulate intracellular calcium flux.
Conclusions: NMU-deficient mice are protected from developing autoantibody-induced inflammatory arthritis.
NMU derived from hematopoietic cells, not neurons, promotes the development of autoantibody-induced
inflammatory arthritis. This effect is mediated by a receptor other than the currently known NMU receptors.
Introduction
Neuromedin U (NMU) is an evolutionarily conserved
short neuropeptide with multiple physiologic effects.
Named for its ability to induce uterine contraction,
NMU has also been reported to play roles in metabolic
and feeding regulation, pain perception, bone remodel-
ing, blood pressure and contraction of smooth muscle
in a variety of organs. NMU is widely expressed, with
highest levels in the central nervous system and gastro-
intestinal tract [1]. NMU has not been detected in the
circulation, suggesting that it acts primarily as a neuro-
transmitter and/or that it is short-lived [2].
Two NMU receptors have been identified, NMUR1
and NMUR2 [1,3]. Both of these are G-protein-coupled
receptors with seven transmembrane domains. In most
species studied, including the mouse, NMUR1 is widely
expressed, predominantly in the gastrointestinal tract
and also in immune cells, whereas the expression of
NMUR2 is limited to the central nervous system. Bind-
ing of NMU to either receptor results in the elevation of
intracellular calcium [4].
Several immunostimulatory activities have been attrib-
uted to NMU. In a mouse Th2 cell clone, stimulation
with NMU led to intracellular calcium flux and the
synthesis and release of IL-4, IL-5, IL-6, IL-10 and IL-13
[5]. More recently, attention has focused on the role of
NMU on cells of the innate immune system. NMU
induced calcium flux in, and degranulation of, mast cells
and was required for mast-cell-mediated inflammation
triggered by local injection of complete Freund’sa d j u -
vant [6]. In a mouse model of asthma, NMU activated
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polysaccharide-induced IL-6 production by macrophages
[8]. These findings suggest that NMU might be an
important driver of inflammatory diseases.
Arthritis can be induced by injecting serum from K/
BxN T cell receptor (TCR) transgenic mice into normal
mice, reflecting the high concentrations of arthritogenic
autoantibodies recognizing glucose-6-phosphate isomer-
ase (GPI) in the K/BxN arthritis model. The develop-
ment of serum-transferred arthritis depends on innate
immune cells, such as neutrophils and mast cells
(although this cell type is under debate) as well as plate-
lets, activating Fc receptors, the alternative pathway of
the complement system, and cytokines [9-17]. Here, we
utilized the K/BxN serum transfer model to test the
hypothesis that NMU promotes inflammatory arthritis.
We also investigated the cellular source of NMU during
the development of arthritis and which of the NMU
receptors mediate its pro-inflammatory effects.
Materials and methods
Mice
Mice with a targeted deletion of the gene encoding
NMU (Nmu
tm1Mko), NMUR1 (Nmur1
tm1Rtor)a n d
NMUR2 (Nmur2
tm1Rtor)o rN T S R 1( Ntsr1
tm1Hmno)o n
the C57BL/6 (B6) background have been described
[18-20]. The nomenclature for the targeted alleles is
obtained from Mouse Genome Informatics [21]. Non-
obese diabetic and B6 mice were obtained from Jackson
Laboratory, Bar Harbor, ME, USA. KRN TCR transgenic
mice were bred in house. Mice were maintained in spe-
cific-pathogen-free colonies at Harvard Medical School
or the University of Minnesota, under protocols
approved by the Harvard Medical Area Standing Com-
mittee on Animals or the University of Minnesota’s
Institutional Animal Care and Use Committee.
Arthritis induction and related studies
K/BxN serum-transferred arthritis was induced and moni-
tored as previously described [22]. Unless otherwise indi-
cated, 150 μL of serum obtained from eight-week-old K/
BxN mice was injected intraperitoneally into 6- to 8-week-
old recipients on days 0 and 2. The arthritis scoring, mea-
surement of ankle thickening and determination of anti-
GPI immunoglobulin G (IgG) titers were performed as
previously described [23]. For arthritis scoring, each paw
was assigned a score of 0 (no arthritis) to 3 (maximum
severity), resulting in a total range of 0 to 12 for an indivi-
dual mouse. Mast cells were identified by toluidine blue
staining, as previously described [11]. Vascular leak studies
and generation of bone-marrow chimeric mice were per-
formed as previously described [22]. Complete blood
counts were performed using a Hemavet 950FS (Drew
Scientific, Dallas, TX, USA).
Calcium flux
Following lysis of red blood cells, splenocytes were
resuspended in Roswell Park Memorial Institute med-
ium plus 10% fetal bovine serum, and were loaded with
Indo-1 AM (10 μg/mL; Invitrogen, Grand Island, NY,
USA) for 30 minutes at 37°C. The cells were washed
and resuspended at 5 × 10
6 cells/mL. Following the
addition of indicated concentrations of rat NMU-23
(sequence YKVNEYQGPVAPSGGFFLFRPRN; Gen-
Script, Piscataway, NJ, USA) or 1 μg/mL ionomycin
( M PB i o m e d i c a l s ,L L C ,S o l o n ,O H ,U S A )i n1 2 . 5 %
dimethyl sulfoxide in water, the cells were analyzed on
an LSRII flow cytometer (BD Biosciences, San Diego,
CA, USA). Data were analyzed using FlowJo software
(Treestar, Ashland, OR, USA).
Statistical analysis
Statistical differences between the mean values for
groups were calculated using an unpaired Student’s two-
tailed t test. Arthritis severity scores were compared
with a repeated-measures analysis of variance. For
experiments involving more than two groups, a post-hoc
Tukey’s multiple comparison test was used. P values <
0.05 were considered significant. Analyses were per-
formed with SPSS 17.0.
Results
We utilized Nmu gene knockout (NMU-KO) mice to
investigate a potential role for NMU in the pathogenesis
of autoantibody-mediated arthritis. After injection of
arthritogenic serum from K/BxN TCR transgenic mice,
NMU-KO mice developed less severe arthritis than lit-
termate controls (Figure 1A, B). Histological examina-
tion of the ankles was consistent with the clinical
scoring, with less inflammation present in the NMU-
deficient mice (Figure 1C). We confirmed that NMU-
KO and control mice maintained equivalent titers of the
pathogenic anti-GPI IgG (Figure 1D). These results indi-
cate that NMU promotes the development of autoanti-
body-induced arthritis.
NMU has been shown to directly activate mast cells to
produce vasodilation and plasma extravasation in
response to complete Freund’s adjuvant [6]. Similarly,
we and others have shown that systemic injection of
serum from K/BxN mice results in rapid induction of
mast-cell- and neutrophil-dependent vascular permeabil-
ity in the paws of mice [22,24,25]. Although some mast-
cell-deficient mouse strains (W/W
v) are protected from
developing K/BxN serum-transferred arthritis [11,16]
whereas others (W
sh)a r en o t[ 2 6 , 2 7 ] ,b o t ht h eW / W
v
and W
sh strains lack the early vascular response induced
by administration of serum from K/BxN mice, verifying
the mast-cell-dependence of this response [22] (BAB,
R W ,C Ba n dD M ,u n p u b l i s h e dw o r k ) .W et h e r e f o r e
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these earliest events induced by K/BxN serum. We first
verified that deficiency of NMU did not interfere with
mast cell differentiation; mast cells were easily identified
and present in equivalent numbers in the skin of B6 and
NMU-KO mice (Figure 2A). In addition, the number
and frequency of other leukocyte subpopulations and
platelets were unaltered in the NMU-KO mice relative
to controls (Figure 2B). Prior studies have shown that
macrophages derived from NMU-KO mice produced
normal levels of IL-1b and TNF, critical arthritogenic
cytokines in K/BxN serum-transferred arthritis and also
IL-12p40 following lipopolysaccharide stimulation. IL-6
production by NMU-KO macrophages was decreased
relative to control macrophages, but IL-6 is dispensable
for serum-transferred arthritis [8,10]. Similarly, mast
cells from NMU-KO mice degranulated normally in vivo
after the injection of NMU or substance P [6]. Consis-
tent with these observations, we found that injection of
K/BxN serum resulted in a similar vascular leak
response in NMU-KO mice and wild-type littermates
(Figure 2C). These findings indicate that the reduction
in arthritis severity in NMU-KO mice was due neither
to impaired differentiation nor a decreased inherent
functional capacity of the main innate immune cell
Figure 1 NMU promotes autoantibody-mediated arthritis.
Serum from arthritic K/BxN mice was injected into NMU-KO mice or
littermate control mice on days 0 and 2. The development of
arthritis was assessed using (A) arthritis scores and (B) ankle
thickening measurements. NMU-KO mice had significantly lower
arthritis scores (P < 0.001, repeated-measures ANOVA) and ankle
thickening (P = 0.001, repeated measures ANOVA), leading to the
conclusion that arthritis severity increases more quickly in wildtype
mice relative to the NMU-KO mice. Data plotted are means ± SEM
from 10 mice per group compiled from three independent
experiments. P-values for individual timepoints calculated using two-
tailed Student’s T-test are also depicted: *P < 0.05; **P < 0.01; ***P <
0.001. (C) Representative ankle sections from the indicated mice at
the peak of arthritis severity were stained with H&E. Arrows indicate
inflammatory infiltrates. Original magnification ×5. (D) Serum was
collected from the mice at the end of the experiment, diluted 1:900,
and assayed by ELISA for the presence of anti-GPI IgG. Data plotted
are arbitrary ELISA absorbance values (means ± SEM) from seven
mice per group compiled from two independent experiments; P =
0.78. ANOVA: analysis of variance; ELISA: enzyme-linked
immunosorbent assay; H&E: hematoxylin and eosin stain; GPI:
glucose-6-phosphate isomerase; IgG, immunoglobulin G; KO:
knockout; NMU: neuromedin U; SEM: standard error of the mean.
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Figure 2 NMU-deficient mice have mast cells, leukocytes,
platelets and an intact early vascular response to arthritogenic
antibodies. (A) Mast cells were enumerated in sections of skin
obtained from control B6 (n = 3) and NMU-KO (n = 4) mice and
stained with toluidine blue. Cells were counted in five ×40 HPF per
mouse and averaged. Plotted values represent the number of mast
cells per HPF in the indicated groups (mean ± SEM). (B) Complete
blood counts from control B6 and NMU-KO mice were performed.
Numbers shown are × 10
9/L ± SD, with four mice per group. (C)
Serum from K/BxN mice was injected intravenously into NMU-KO
mice (red) or littermate control mice (black). Vascular leak in the
hindpaw was monitored by intravital confocal microscopic
evaluation of extravasation of the intravascular tracer, Angiosense
680. Each line represents one mouse. B6: C57BL/6; HPF: high power
field; KO: knockout; MFI; mean fluorescence intensity; NMU:
neuromedin U; SD: standard deviation; SEM: standard error of the
mean.
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arthritis in this model. In addition, the arthritis-promot-
ing effect of NMU likely occurred at a timepoint after
the initial vascular leak response.
NMU is best known as a neurotransmitter. However,
other cell types, including hematopoietic cells, express
NMU. Prior studies have not established whether NMU
production by hematopoietic cells or stromal cells (for
example, neurons) is responsible for its pro-inflamma-
tory effects [6-8]. To address this question, we generated
bone-marrow chimeric mice using wildtype B6 mice and
NMU-KO mice in each possible donor:recipient combi-
nation. Following bone marrow engraftment, we induced
arthritis with serum. Mice that had received wildtype
bone marrow developed more severe arthritis than those
that received NMU-KO bone marrow, irrespective of
the NMU status of the recipient mouse (Figure 3).
These findings establish that NMU expression by bone-
marrow-derived cells, not neurons or other stromal
cells, is responsible for the pro-arthritogenic activity of
NMU.
Two main receptors for NMU have been identified,
NMUR1 and NMUR2. The former is widely expressed,
whereas expression of the latter is restricted essentially
to the central nervous system. We utilized gene-knock-
out mice to determine which receptor mediates the pro-
inflammatory activity of NMU. Mice lacking NMUR1,
NMUR2 or both receptors developed arthritis in an
essentially indistinguishable way from control mice (Fig-
ure 4). This observation suggests that another NMU
receptor may be involved.
The only other NMU receptor reported in the litera-
ture is a heterodimer of the neurotensin receptor 1
(NTSR1) and the growth hormone secretagogue
receptor 1 b, identified in human lung cancer cells [28].
Therefore, we investigated the possibility that this recep-
tor was responsible for the arthritis-promoting effect of
NMU. Ntsr1-deficient mice developed serum-transferred
arthritis equivalent to that of controls (Figure 5). We
therefore bred mice lacking Nmur1, Nmur2 and Ntsr1.
These mice, lacking all known NMU receptors, also
remained susceptible to serum-transferred arthritis, even
when given doses of serum lower than usual in an effort
to accentuate any potential differences between the
groups (Figure 5). This result was unexpected, and
prompted us to perform additional in vitro studies to
determine if cellular responses to NMU were intact in
these triple-NMU-receptor knockout mice.
NMU stimulation of cells causes intracellular calcium
flux. Stimulation of splenocytes from Nmur1/Nmur2/
Ntsr1 triple-knockout mice with a range of concentra-
tions of NMU provoked intracellular calcium flux indis-
tinguishable from that induced in splenocytes from
control mice, demonstrating that the splenocytes from
these triple-knockout mice must utilize another
mechanism to detect NMU (Figure 6). Considered
together, our findings indicate that NMU can promote
the development of autoantibody-mediated arthritis
through a receptor distinct from the currently known
NMU receptors.
Discussion
Neuropeptides are increasingly recognized as potential
contributors to inflammatory diseases. For instance, the
neuropeptide substance P is involved in a variety of
inflammatory conditions, including being upregulated in
the inflamed synovium of patients with rheumatoid
arthritis [29]. In addition, catecholamine-producing cells
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Figure 3 NMU production by bone marrow-derived cells promotes autoantibody-mediated arthritis. Bone marrow chimeric mice were
generated in the four indicated combinations. Following bone marrow engraftment, serum from K/BxN mice was injected on days 0 and 2 and
the development of arthritis was assessed at the indicated timepoints. Data plotted are means ± SEM and represent one of two independent
experiments with a total of eight mice per genotype. B6®B6 versus NMU-KO®B6, P = 0.006; B6®B6 versus NMU-KO®NMU-KO, P = 0.022;
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error of the mean.
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patients with inflammatory arthritis [30]. Understanding
how neuropeptides promote inflammatory diseases is
expected to lead to new therapeutic approaches.
Based on a series of reports describing the pro-inflam-
matory properties of NMU [6-8], we tested the
hypothesis that NMU can promote the development of
autoantibody-mediated arthritis. Indeed, our results
demonstrated that mice lacking NMU were protected
from K/BxN serum-transferred arthritis. This protection
was not due to impaired differentiation of the key innate
immune cell types (that is, neutrophils, platelets and
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NMU interfere with the earliest vascular events pro-
voked by injection of autoantibodies, but more likely at
a later time. NMU can directly activate effector cells,
such as mast cells, eosinophils and macrophages, to eli-
cit a variety of cellular responses including degranula-
tion, adhesion, chemotaxis and production of the pro-
inflammatory cytokine IL-6 [6-8]. Therefore, it is likely
that NMU acts on multiple cell types to elicit a variety
of pro-inflammatory activities that drive the inflamma-
tory arthritis in this model.
Although it is known that NMU can be produced by
hematopoietic cells [8,31], most prior studies have
focused on neurons as being the most likely source of
pro-inflammatory NMU [6-8]. Our reciprocal bone-mar-
row transplantation experiments showed clearly that
NMU derived from hematopoietic cells was critical for
its pro-arthritogenic activity. Our findings are consistent
with the finding that NMU is not a marker of peripheral
sympathetic or sensory nerve fibers [3]. Similarly, our
results support previous findings that substance P and
neuropeptide Y are neuropeptides produced not only by
neurons but also by immune cells [29,32], and that
inflammatory arthritis is accompanied by a loss of sym-
pathetic nerve fibers which appear to be replaced by
synovial cells that synthesize catecholamines [30]. Thus,
although neuropeptides are typically initially character-
ized based on their expression in neurons, their pro-
inflammatory properties might be attributed instead to
their expression by cells of the immune system, as we
have shown. Therefore, the involvement of a neuropep-
tide in an inflammatory disease does not necessarily
imply neuro-immune connections or neuro-immune
cross-talk other than expression of similar neuropeptides
by these cell types.
Additionally, although it is theoretically possible that
NMU-deficient mice were protected from autoantibody-
induced arthritis due to developmental or metabolic
abnormalities in the mice, our finding that the protec-
tive effect of NMU deficiency was transferrable with
bone marrow-derived cells suggests that such a scenario
is unlikely.
Defining the receptors that a pro-inflammatory sub-
stance engages to elicit inflammation is important for
the development of potential therapeutic agents.
NMUR1 is widely expressed, and Nmur1-deficient mice
have impaired contraction of certain smooth muscle tis-
sues in the gastrointestinal tract [33]. NMUR2 is
expressed primarily in the central nervous system, and
Nmur2-deficient mice have been shown to have
impaired responses to pain in some assays; in contrast,
these pain responses were normal in Nmur1-deficient
mice [20]. With respect to inflammatory responses,
inflammation induced by the injection of complete
Freund’s adjuvant was normal in mice lacking both
receptors [20]. Similarly, we have shown here that auto-
antibody-induced arthritis was unimpaired in these
same Nmur1/Nmur2-deficient mice. We further have
shown that the only other reported functional NMU
receptor, a heterodimer of NTSR1 and the growth hor-
mone secretagogue receptor 1 b, was also dispensable
for the development of serum-transferred arthritis.
Recent evidence, however, suggests that NMU-induced
suppression of food intake and weight gain remained
intact in mice lacking NTSR1, suggesting that NTSR1
may not serve as an NMU receptor in vivo [34]; this is
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possible that the related NTSR2 could serve as an NMU
receptor, though this has not been demonstrated
experimentally.
Our results suggest that an as-yet-unidentified NMU
receptor is responsible for the pro-inflammatory effects
of NMU. It is likely, based on the structure of the
known NMU receptors, that this receptor will belong to
a large family of seven transmembrane spanning G-pro-
tein-coupled receptors. It is of course possible that the
expression of this putative additional NMU receptor is
upregulated in the mice we studied here, as a physiolo-
gic compensatory mechanism for the absence of the
known NMU receptors, and that its contribution to the
pro-inflammatory activities of NMU is therefore appar-
ent only in the absence of the known NMU receptors. It
has been shown, for instance, that the expression of
NMUR1 is increased in macrophages derived from
NMU-KO mice, supporting the notion that such com-
pensatory mechanisms might exist [8]. Further investiga-
tions such as the use of NMUR1- and NMUR2-specific
short-acting antagonists and/or identification of this
putative additional NMU receptor should help to clarify
this point.
In summary, we have shown that mice genetically
deficient in NMU expression were protected from devel-
oping autoantibody-induced inflammatory arthritis. In
this model, bone-marrow-derived cells rather than neu-
rons served as the critical source of NMU. The arthrito-
genic activity of NMU may be mediated via a receptor
other than the currently defined NMU receptors. Our
results indicate that targeting NMU or its receptors
could be an attractive approach to therapeutic interven-
tion in inflammatory arthritis, but also suggest that
further delineation and definition of the key NMU
receptors will first be required. More broadly, our find-
ings demonstrate that neuropeptides expressed by
immune cells can be important contributors to the
pathogenesis of inflammatory arthritis.
Conclusions
NMU produced by bone-marrow-derived cells promoted
autoantibody-mediated arthritis in mice. The arthrito-
genic activity of NMU was mediated by a receptor other
than the currently known NMU receptors. This study
points to NMU as a new potential therapeutic target in
inflammatory arthritis.
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